myocardial ischemia-reperfusion injury following cardiac stenting
Conditions
Interventions
Control group:Visual and palpation examinations assess morphology, noting color, size, and location. Infrared thermography, pain measurement devices, and electrical resistance meters are used to detec
MIRI group:Visual and palpation examinations assess morphology, noting color, size, and location. Infrared thermography, pain measurement devices, and electrical resistance meters are used to detect s
Sponsors
The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: MIRI group: (1)Patients who meet the diagnostic criteria for chronic coronary syndrome according to the Guidelines for the Diagnosis of Chronic Coronary Syndrome issued by the European Society of Cardiology (ESC) in 2019 (2)The patient underwent a PCI procedure and had at least one stent implanted within one week; (3)The patients are of any race and gender with an age range of 18 years old or above and below 85 years old; (4)Patients are willing to participate in the trial and sign an informed consent form. Note: Patients who meet all 4 of these criteria are eligible for inclusion in this study. Control group: (1)The subject is in good health with no cardiovascular diseases or mental illnesses; (2) The subject's race and gender are not restricted and the age range is from 18 years old and above to below 85 years old. (3) The subject are willing to participate in the trial and sign an informed consent form. Note: Subjects who meet all 3 of these criteria are eligible for inclusion in this study.
Exclusion criteria
Exclusion criteria: MIRI group: (1)For STEMI patients the ECG manifestations are persistent ST-segment elevation (at least two consecutive ST-segment elevations starting from the J point: 1) =2.5mm in V2-V3 leads for males under 40 years old or =2mm for males over 40 years old or =1.5mm for females regardless of age; 2) =1mm in other leads except for left ventricular hypertrophy or left bundle branch block; 3) =0.5mm in right precordial leads V3R-V4R or posterior leads V7-V9). (2)The patient suffers from malignant tumors severe infectious diseases inflammatory diseases autoimmune diseases hematological diseases and acute cerebral infarction. (3)The patient is suffering from clinically difficult-to-diagnose bullous skin diseases granulomatous skin diseases metabolic skin diseases and connective tissue diseases. (4)The patient has participated in any other drug study or treatment research using an unapproved medication within the past 3 months. (5)The patient is a pregnant or lactating woman. (6)The patient has a mental health condition or severe psychological impairment that prevents them from cooperating with the treatment or study. Note: Patients are excluded if they meet any of these criteria. Control group: (1)The subject suffers from anxiety depression cognitive impairment and has allergic constitution. (2)The subject is a pregnant or lactating woman. (3)The subject is simultaneously participating in another clinical trial. Note: Subjects are excluded if they meet any of these criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Shape sensitization point; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain sensitization point;Electrical sensitization point;Heat sensitization point; | — |
Countries
China
Contacts
Public ContactQiao Haifa
Shaanxi University of Chinese Medicine
Outcome results
None listed